Crispr Therapeutics AG (NASDAQ:CRSP) President Rodger Novak sold 17,310 shares of Crispr Therapeutics stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $35.09, for a total value of $607,407.90. Following the completion of the transaction, the president now owns 1,130,697 shares of the company’s stock, valued at $39,676,157.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of CRSP stock opened at $35.15 on Friday. Crispr Therapeutics AG has a 52 week low of $22.22 and a 52 week high of $73.90. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -20.56 and a beta of 3.48.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Thursday, November 8th. The company reported ($1.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The company had revenue of $0.56 million during the quarter, compared to analyst estimates of $2.64 million. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. The business’s revenue was down 76.6% on a year-over-year basis. Equities research analysts predict that Crispr Therapeutics AG will post -3.26 EPS for the current year.
A number of hedge funds have recently modified their holdings of the business. Signaturefd LLC boosted its stake in Crispr Therapeutics by 123.8% in the second quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock valued at $138,000 after acquiring an additional 1,300 shares during the period. Bank of America Corp DE boosted its stake in Crispr Therapeutics by 26.5% in the second quarter. Bank of America Corp DE now owns 9,407 shares of the company’s stock valued at $553,000 after acquiring an additional 1,972 shares during the period. TRUE Private Wealth Advisors acquired a new position in Crispr Therapeutics in the third quarter valued at approximately $122,000. Vanguard Group Inc. boosted its stake in Crispr Therapeutics by 6.6% in the third quarter. Vanguard Group Inc. now owns 52,023 shares of the company’s stock valued at $2,307,000 after acquiring an additional 3,200 shares during the period. Finally, Vanguard Group Inc boosted its position in shares of Crispr Therapeutics by 6.6% during the third quarter. Vanguard Group Inc now owns 52,023 shares of the company’s stock worth $2,307,000 after buying an additional 3,200 shares during the period. Institutional investors own 43.81% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Further Reading: Cost of Debt
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.